论文部分内容阅读
同种异基因骨髓移植(BMT)已日益增多地用于治疗再生障碍性贫血(再障)、免疫缺陷综合征和恶性肿瘤。尽管治疗总的说来是成功的,但移植后会发生若干严重甚至潜在致命的并发症。 BMT前的大剂量化疗、全身放疗(TBI)或全身淋巴结照射(TLI)是为了充分地抑制受者的免疫功能,以期达到永久性植活及预防免疫排斥。BMT治疗恶性肿瘤还须彻底杀灭肿瘤细胞。移植后供者骨髓细胞在受者体内植活
Allogeneic bone marrow transplantation (BMT) has been increasingly used to treat aplastic anemia (aplastic anemia), immunodeficiency syndromes and malignancies. Although treatment in general has been successful, several serious and potentially fatal complications occur after transplantation. High-dose chemotherapy, systemic radiotherapy (TBI) or systemic lymph node irradiation (TLI) before BMT is intended to fully suppress the recipient’s immune function in order to achieve permanent engraftment and prevent immune rejection. BMT treatment of malignant tumors must also completely kill tumor cells. Donor bone marrow cells are implanted in recipients after transplantation